ABSTRACT
Urogenital atrophy is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to estrogen decline. Local estrogen therapy if effective to relieve signs and symptoms of vaginal atrophy without causing an elevation of serum estrogen levels. Although there are no big studies addressing the safety of this type of treatment, it can be maintained over long periods to avoid annoying symptoms. Special care must be taken with women with breast cancer in whom the effective dose must be titrated to avoid an increase in serum estrogens over the levels usually observed in postmenopausal women.
Subject(s)
Humans , Female , Female Urogenital Diseases/drug therapy , Estradiol/administration & dosage , Estriol/administration & dosage , Estrogens/administration & dosage , Administration, Intravaginal , Atrophy/drug therapy , Breast Neoplasms , Climacteric , Ointments , Tablets , Vaginal Creams, Foams, and Jellies , Vagina , Vagina/pathologyABSTRACT
OBJECTIVE: To compare serum estradiol (E2) level in Thai surgical menopausal women before and after receiving a daily dose of 1 mg oral micronized 17 beta-estradiol. DESIGN: Experimental study (before and after treatment). SETTING: Gynecological ward, Hatyai regional hospital. PATIENTS: 40 premenopausal Thai women who had undergone total abdominal hysterectomy with bilateral salpingoooporectomy (Surgical menopause) for 1 week previously due to benign gynecologic conditions were recruited in the present study. These women had no contraindications for receiving hormonal replacement therapy and no history of any hormonal intake in the past. INTERVENTION : All women were assigned to receive a 1 mg micronized 17 beta-estradiol (Estrofem, Novo Nordisk A/S, Denmark) orally applied at bedtime (08.00 p.m.) each day. MEASUREMENTS: Serum estradiol (E2) levels were measured before and after treatment at 4, 8 and 12 weeks. The hormonal measurement was performed using the ELFA-technique (Enzyme Linked Fluorescent Assay). RESULTS: Four cases were excluded due to loss to follow up. Of the remaining 36 cases, the mean age (+/- SD) and the body mass index were 46.27 +/- 5. 74 years and 23.72 +/- 2.92 kg/m2, respectively. Serum E2 level significantly increased from baseline value at 4, 8 and 12 weeks (mean (+/- SD) of E2 level at 0, 4, 8 and 12 weeks: 3.82 +/- 6.30 pg/ml, 117.11 +/- 92.86 pg/ml, 135.28 +/- 91.38 pg/ml and 164.48 +/- 78.94 pg/ml, p < 0.05) respectively. CONCLUSION: A daily dose of 1 mg oral micronized 17 beta-estradiolfor 12 weeks increased the serum E2 level to the follicular phase level of the normal menstrual cycle.
Subject(s)
Adult , Dose-Response Relationship, Drug , Drug Combinations , Estradiol/administration & dosage , Estriol/administration & dosage , Estrogen Replacement Therapy , Humans , Middle Aged , ThailandABSTRACT
Analise do estriol salivar feita em 18 gestantes, sendo nove gravidas, com OGTT-3hs alterado durante o periodo pre-natal, controladas somente com dieta, classe A de Priscilla White, pertencentes ao grupo um de estudo, e nove gestantes que fizeram uso de insulina durante a gravidez, sendo tres tipo II e seis tipo I (insulino-dependentes), pertencentes ao grupo II de estudo, acompanhadas no pre-natal da Escola Paulista de Medicina no periodo de janeiro de 1987 a julho de 1989. A coleta foi realizada semanalmente, obtendo-se tres amostras, em intervalos de duas horas...
Subject(s)
Humans , Female , Pregnancy , Diabetes Mellitus/physiopathology , Estriol/analysis , Saliva , Blood Glucose/analysis , Estriol/administration & dosage , Estriol/metabolism , Fetal Distress/prevention & control , Fetal Monitoring , Prospective Studies , RadioimmunoassayABSTRACT
Se estudia la repuesta vaginal al succinato de estriol en 40 pacientes oncoginecológicas, 20 de ellas irradiadas (grupo estudio) y 20 no irradiadas (grupo control) ambas con menopausia artificial instalada. Los índices clínicos y citológicos previo a la terapia estrogénica, en el grupo de pacientes irradiadas fueron significativamente mas severos, con una incidencia de atrifia vaginal postmenopausica alta, que guarda relación con el tipo y dosis de radioterapia. La respuesta al tratamiento en ambos grupos fue muy favorable, sin haber diferencias estadísticamente significativas entre ellos, esto se reflejó en un marcado cambio del frotis vaginal, indicando un intenso efecto estrogénico, con una correlación directa entre la respuesta clínica y la proliferación celular, concluyendo que la vagina de pacientes irradiadas responde de manera similar al estímulo estrogénico. La dosis de 4 mg diarios de succinato de estriol, en terapia continua, son suficientes, para el alivio de los síntomas vaginales en pacientes oncoginecológicas, irradiadas o no, traduciéndose finalmente en un mejoramiento de la calidad de vida